FOLH1 and posterior cortical atrophy: The development of radiopharmaceuticals that directly target the extracellular domain of the prostate-specific membrane antigen (PSMA) resulted in an improvement in the detection of PCa lesions, and this approach is now recommended for PET/CT imaging of PCa recurrence.